Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study

Jeffrey A. Cohen, Ludwig Kappos, Philipp von Rosenstiel et al.|Journal of Neurology Neurosurgery & Psychiatry|2015

Cited by 163